Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ENZ Stock Summary
Top 10 Correlated ETFs
ENZ
In the News
Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results.
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”) and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the “Asset Purchase Agreement”), by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.
Top Sectors to Explore for Penny Stocks to Buy
Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stock Psychology: Developing a Winning Mindset
Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Enzo Biochem (ENZ) Stock Up 72% Today?
Enzo Biochem (NYSE: ENZ ) stock is rocketing higher on Friday after the company agreed to an asset sale with Labcorp (NYSE: LH ). That asset sale has Enzo Biochem agreeing to divest its Clinical Laboratory division to Labcorp.
Enzo Biochem, Inc. (ENZ) Q1 2023 Earnings Call Transcript
Enzo Biochem, Inc. (NYSE:ENZ ) Q1 2023 Earnings Conference Call December 13, 2022 8:30 AM ET Company Participants Unidentified Company Representative - IR Hamid Erfanian - CEO Patricia Eckert - Interim CFO Conference Call Participants Operator Greetings and welcome to the Enzo Biochem, Incorporated First Quarter 2023 Earnings Call. At this all participants are in a listen-only mode.
Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th
Conference Call and Webcast Scheduled for December 13 th , 8:30 AM ET
Enzo Biochem, Inc. Announces Date of Annual Shareholders' Meeting
NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that its Annual Shareholders' Meeting will be held on January 31, 2023. Shareholders must submit proposals and/or director nominations in connection with meeting no later than November 18, 2022 to be considered timely.
Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th
Conference Call and Webcast Scheduled for October 1 4 , 202 2 , 8 : 3 0 a m ET
Enzo Biochem, Inc. (ENZ) CEO Hamid Erfanian on Q3 2022 Results - Earnings Call Transcript
Enzo Biochem, Inc. (NYSE:ENZ ) Q3 2022 Earnings Conference Call June 10, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Hamid Erfanian - Chief Executive Officer David Bench - Chief Financial Officer Conference Call Participants J. P. Sullivan - Potomac Capital Operator Greetings and welcome to the Enzo Biochem Third Quarter 2022 Financial Results and Business Update.
ENZ Financial details
ENZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-07-31
Metric | History | 2019-07-31 | 2020-07-31 | 2021-07-31 | 2022-07-31 | 2023-07-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.71 | 1.6 | 2.44 | 2.21 | 0.63 | |
Net income per share | -2.09 | -0.71 | 0.07 | -0.47 | 0.41 | |
Operating cash flow per share | 0.1 | -0.36 | 0.01 | -0.34 | -0.75 | |
Free cash flow per share | -0.07 | -0.41 | -0.08 | -0.41 | -0.81 | |
Cash per share | 1.27 | 1.01 | 0.9 | 0.45 | 1.68 | |
Book value per share | 1.82 | 1.23 | 1.42 | 1.12 | 1.6 | |
Tangible book value per share | 1.64 | 1.06 | 1.26 | 0.82 | 1.6 | |
Share holders equity per share | 1.82 | 1.23 | 1.42 | 1.12 | 1.6 | |
Interest debt per share | 0.11 | 0.69 | 0.47 | 0.43 | 0.14 | |
Market cap | 185.14M | 113.13M | 157.1M | 117.19M | 72.61M | |
Enterprise value | 129.6M | 98.05M | 166.25M | 116.18M | -2.76M | |
P/E ratio | -1.87 | -3.34 | 45.87 | -5.19 | 3.58 | |
Price to sales ratio | 2.28 | 1.49 | 1.33 | 1.09 | 2.34 | |
POCF ratio | 38.52 | -6.59 | 405.95 | -7.06 | -1.96 | |
PFCF ratio | -55.77 | -5.85 | -38.8 | -5.84 | -1.83 | |
P/B Ratio | 2.15 | 1.94 | 2.29 | 2.15 | 0.93 | |
PTB ratio | 2.15 | 1.94 | 2.29 | 2.15 | 0.93 | |
EV to sales | 1.6 | 1.29 | 1.41 | 1.09 | -0.09 | |
Enterprise value over EBITDA | 1.6 | -6.52 | 13.27 | -10.6 | 0.23 | |
EV to operating cash flow | 26.97 | -5.71 | 429.6 | -7 | 0.07 | |
EV to free cash flow | -39.04 | -5.07 | -41.06 | -5.79 | 0.07 | |
Earnings yield | -0.53 | -0.3 | 0.02 | -0.19 | 0.28 | |
Free cash flow yield | -0.02 | -0.17 | -0.03 | -0.17 | -0.55 | |
Debt to equity | 0.06 | 0.56 | 0.33 | 0.38 | 0.09 | |
Debt to assets | 0.05 | 0.29 | 0.2 | 0.21 | 0.06 | |
Net debt to EBITDA | -0.68 | 1 | 0.73 | 0.09 | 6.22 | |
Current ratio | 5.09 | 2.1 | 2.71 | 2.21 | 2.46 | |
Interest coverage | 0 | 0 | 0 | -97.53 | 0 | |
Income quality | 1.93 | 0.6 | 0.05 | 0.91 | -1.82 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.55 | 0.65 | 0.38 | 0.5 | 0.88 | |
Research and developement to revenue | 0.04 | 0.06 | 0.03 | 0.04 | 0.13 | |
Intangibles to total assets | 0.08 | 0.07 | 0.07 | 0.08 | 0 | |
Capex to operating cash flow | -1.69 | 0.13 | -11.46 | 0.21 | 0.07 | |
Capex to revenue | -0.1 | -0.03 | -0.04 | -0.03 | -0.09 | |
Capex to depreciation | -2.68 | -0.78 | -1.67 | -1.23 | -1.03 | |
Stock based compensation to revenue | 0.02 | 0.02 | 0.01 | 0.02 | 0.1 | |
Graham number | 9.23 | 4.44 | 1.51 | 3.43 | 3.86 | |
ROIC | -33.91 | -0.25 | 0.04 | -0.21 | -0.41 | |
Return on tangible assets | -1.01 | -0.32 | 0.03 | -0.26 | 0.17 | |
Graham Net | 1.09 | 0.09 | 0.26 | -0.07 | 0.95 | |
Working capital | 65.44M | 35.96M | 44.51M | 29.8M | 58.47M | |
Tangible asset value | 77.54M | 50.39M | 60.89M | 47.01M | 78.46M | |
Net current asset value | 60.84M | 14.61M | 25.48M | 12.96M | 55.04M | |
Invested capital | 0.06 | 0.56 | 0.33 | 0.38 | 0.09 | |
Average receivables | 11.94M | 9.94M | 9.67M | 10.86M | 8.16M | |
Average payables | 8.39M | 7.88M | 8.31M | 8.32M | 6.04M | |
Average inventory | 7.56M | 7.81M | 10.22M | 14.03M | 11.68M | |
Days sales outstanding | 48.29 | 43.89 | 31.62 | 39.26 | 56.5 | |
Days payables outstanding | 45.72 | 59.4 | 46.22 | 47.7 | 66.93 | |
Days of inventory on hand | 49.42 | 54.38 | 71.98 | 86.4 | 148.64 | |
Receivables turnover | 7.56 | 8.32 | 11.54 | 9.3 | 6.46 | |
Payables turnover | 7.98 | 6.15 | 7.9 | 7.65 | 5.45 | |
Inventory turnover | 7.39 | 6.71 | 5.07 | 4.22 | 2.46 | |
ROE | -1.15 | -0.58 | 0.05 | -0.41 | 0.26 | |
Capex per share | -0.17 | -0.05 | -0.09 | -0.07 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2024-01-31 for Q2
Metric | History | 2023-01-31 | 2023-04-30 | 2023-07-31 | 2023-10-31 | 2024-01-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.34 | 0.33 | -0.4 | 0.16 | 0.17 | |
Net income per share | -0.22 | -0.3 | 1.18 | -0.13 | -0.06 | |
Operating cash flow per share | -0.13 | -0.1 | -0.35 | -0.27 | -0.18 | |
Free cash flow per share | -0.15 | -0.12 | -0.36 | -0.27 | -0.18 | |
Cash per share | 0.1 | 0.05 | 1.69 | 1.38 | 1.29 | |
Book value per share | 0.67 | 0.38 | 1.61 | 1.48 | 1.4 | |
Tangible book value per share | 0.37 | 0.08 | 1.61 | 1.48 | 1.4 | |
Share holders equity per share | 0.67 | 0.38 | 1.61 | 1.48 | 1.4 | |
Interest debt per share | 0.38 | 0.61 | -0.03 | 0.14 | 0.09 | |
Market cap | 65.3M | 121.98M | 72.08M | 67.25M | 63.62M | |
Enterprise value | 78.85M | 141.27M | -3.3M | 5.07M | 5.56M | |
P/E ratio | -1.53 | -2.07 | 0.31 | -2.54 | -5.2 | |
Price to sales ratio | 4 | 7.57 | -3.67 | 8.61 | 7.44 | |
POCF ratio | -10.54 | -24.14 | -4.23 | -5.03 | -7.12 | |
PFCF ratio | -9.24 | -21.32 | -4.09 | -4.93 | -7.1 | |
P/B Ratio | 1.99 | 6.44 | 0.92 | 0.91 | 0.9 | |
PTB ratio | 1.99 | 6.44 | 0.92 | 0.91 | 0.9 | |
EV to sales | 4.83 | 8.77 | 0.17 | 0.65 | 0.65 | |
Enterprise value over EBITDA | -6.66 | -20.86 | -0.26 | -2.94 | -4.8 | |
EV to operating cash flow | -12.72 | -27.95 | 0.19 | -0.38 | -0.62 | |
EV to free cash flow | -11.16 | -24.7 | 0.19 | -0.37 | -0.62 | |
Earnings yield | -0.16 | -0.12 | 0.8 | -0.1 | -0.05 | |
Free cash flow yield | -0.11 | -0.05 | -0.24 | -0.2 | -0.14 | |
Debt to equity | 0.57 | 1.16 | 0.09 | 0.09 | 0.06 | |
Debt to assets | 0.24 | 0.3 | 0.06 | 0.07 | 0.04 | |
Net debt to EBITDA | -1.15 | -2.85 | -5.95 | 36.11 | 50.18 | |
Current ratio | 1.13 | 0.76 | 2.46 | 3.05 | 3.2 | |
Interest coverage | -193.29 | -1.38 | -1.65 | 0 | 0 | |
Income quality | 0.55 | 0.33 | -0.3 | 2.02 | 10.36 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.72 | 0.27 | -1.18 | 0.9 | 0.59 | |
Research and developement to revenue | 0.09 | 0.06 | -0.03 | 0.11 | 0.07 | |
Intangibles to total assets | 0.1 | 0.1 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.14 | 0.13 | 0.03 | 0.02 | 0 | |
Capex to revenue | -0.05 | -0.04 | 0.03 | -0.03 | 0 | |
Capex to depreciation | -1.39 | -1.03 | -0.95 | -0.94 | -0.09 | |
Stock based compensation to revenue | 0.04 | 0.06 | -0.04 | 0.15 | 0.06 | |
Graham number | 1.82 | 1.6 | 6.54 | 2.1 | 1.38 | |
ROIC | -0.17 | -0.2 | 0.72 | -0.07 | -0.06 | |
Return on tangible assets | -0.15 | -0.23 | 0.47 | -0.06 | -0.03 | |
Graham Net | -0.46 | -0.72 | 0.96 | 0.88 | 0.88 | |
Working capital | 4.18M | -10.15M | 58.47M | 59.17M | 55.64M | |
Tangible asset value | 25.38M | 11.48M | 78.46M | 74.28M | 70.78M | |
Net current asset value | -7.24M | -21.13M | 55.04M | 55.98M | 52.62M | |
Invested capital | 0.57 | 1.16 | 0.09 | 0.09 | 0.06 | |
Average receivables | 11.19M | 10.25M | 7.22M | 4.49M | 4.65M | |
Average payables | 10.65M | 13.42M | 8.61M | 2.77M | 1.64M | |
Average inventory | 15.76M | 15.51M | 11.61M | 7.77M | 7.7M | |
Days sales outstanding | 59.86 | 53.84 | -22.01 | 48.21 | 53.83 | |
Days payables outstanding | 78.72 | 84.87 | 63.54 | 40.58 | 27.4 | |
Days of inventory on hand | 93.84 | 95.1 | 141.1 | 157.1 | 162.16 | |
Receivables turnover | 1.5 | 1.67 | -4.09 | 1.87 | 1.67 | |
Payables turnover | 1.14 | 1.06 | 1.42 | 2.22 | 3.28 | |
Inventory turnover | 0.96 | 0.95 | 0.64 | 0.57 | 0.56 | |
ROE | -0.32 | -0.78 | 0.73 | -0.09 | -0.04 | |
Capex per share | -0.02 | -0.01 | -0.01 | -0.01 | 0 |
ENZ Frequently Asked Questions
What is Enzo Biochem, Inc. stock symbol ?
Enzo Biochem, Inc. is a US stock , located in New york of Ny and trading under the symbol ENZ
What is Enzo Biochem, Inc. stock quote today ?
Enzo Biochem, Inc. stock price is $1.27 today.
Is Enzo Biochem, Inc. stock public?
Yes, Enzo Biochem, Inc. is a publicly traded company.